CUSIP 09061G101 · who reports it, how much, and how much it matters to them
45 of the 720 hedge fund managers we track reported shares of Biomarin Pharmaceutical Inc (Nasdaq: BMRN) on Form 13F for 30 June 2026. Between them they reported USD 1.2bn. The largest position belongs to Viking Global Investors, at USD 436m. The manager with the most riding on it is Boone Capital Management, where it is 7.8% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Viking Global Investors4 funds on PPLI.com | USD 436m | 1.2% |
| 2 | Deep Track Capital1 fund on PPLI.com | USD 189m | 2.8% |
| 3 | Millennium Management6 funds on PPLI.com | USD 119m | 0.0% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 64m | 0.0% |
| 5 | Balyasny Asset Management25 funds on PPLI.com | USD 60m | 0.1% |
| 6 | Hudson Bay Capital Management8 funds on PPLI.com | USD 47m | 0.1% |
| 7 | Palo Alto Investors6 funds on PPLI.com | USD 39m | 5.4% |
| 8 | Eagle Health Investments1 fund on PPLI.com | USD 36m | 5.9% |
| 9 | Boone Capital Management1 fund on PPLI.com | USD 33m | 7.8% |
| 10 | Renaissance Technologies13 funds on PPLI.com | USD 26m | 0.0% |
| 11 | Freestone Grove Partners1 fund on PPLI.com | USD 21m | 0.1% |
| 12 | Sofinnova Investments1 fund on PPLI.com | USD 21m | 1.1% |
| 13 | Sphera Funds Management1 fund on PPLI.com | USD 19m | 2.5% |
| 14 | Walleye Capital8 funds on PPLI.com | USD 16m | 0.1% |
| 15 | Bridgewater Associates45 funds on PPLI.com | USD 16m | 0.1% |
| 16 | Redmile Group10 funds on PPLI.com | USD 15m | 1.0% |
| 17 | Eversept Partners3 funds on PPLI.com | USD 14m | 0.7% |
| 18 | Capital Fund Management S.A.12 funds on PPLI.com | USD 13m | 0.1% |
| 19 | Engineers Gate Manager1 fund on PPLI.com | USD 10m | 0.1% |
| 20 | Squarepoint Ops7 funds on PPLI.com | USD 6.1m | 0.0% |
| 21 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 5.9m | 0.0% |
| 22 | Edgestream Partners5 funds on PPLI.com | USD 5.8m | 0.2% |
| 23 | Marshall Wace LLP84 funds on PPLI.com | USD 5.6m | 0.0% |
| 24 | D. E. Shaw & Co.15 funds on PPLI.com | USD 5.3m | 0.0% |
| 25 | Persistent Asset Partners10 funds on PPLI.com | USD 4.6m | 1.4% |
| 26 | Boothbay Fund Management2 funds on PPLI.com | USD 3.7m | 0.0% |
| 27 | Atom Investors1 fund on PPLI.com | USD 3m | 0.3% |
| 28 | Two Sigma Investments35 funds on PPLI.com | USD 1.6m | 0.0% |
| 29 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 1.4m | 0.1% |
| 30 | Verition Fund Management3 funds on PPLI.com | USD 1.3m | 0.0% |
| 31 | Greenland Capital Management1 fund on PPLI.com | USD 1.1m | 0.1% |
| 32 | The Quarry1 fund on PPLI.com | USD 1m | 0.1% |
| 33 | Aquatic Capital Management3 funds on PPLI.com | USD 986,000 | 0.0% |
| 34 | Voleon Capital Management13 funds on PPLI.com | USD 943,000 | 0.0% |
| 35 | CM Management1 fund on PPLI.com | USD 858,000 | 0.5% |
| 36 | Gamco Asset Management1 fund on PPLI.com | USD 744,000 | 0.0% |
| 37 | Holocene Advisors2 funds on PPLI.com | USD 668,000 | 0.0% |
| 38 | Capstone Investment Advisors25 funds on PPLI.com | USD 559,000 | 0.0% |
| 39 | CIBC Asset Management69 funds on PPLI.com | USD 339,000 | 0.0% |
| 40 | Prelude Capital Management9 funds on PPLI.com | USD 332,000 | 0.0% |
| 41 | Landscape Capital Management4 funds on PPLI.com | USD 320,000 | 0.0% |
| 42 | Oxford Asset Management LLP2 funds on PPLI.com | USD 313,000 | 0.2% |
| 43 | ISAM Funds (UK)1 fund on PPLI.com | USD 309,000 | 0.2% |
| 44 | Entrypoint Capital1 fund on PPLI.com | USD 299,000 | 0.1% |
| 45 | Summit Global Investments1 fund on PPLI.com | USD 1,869 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Boone Capital Management | USD 33m | 7.8% |
| 2 | Eagle Health Investments | USD 36m | 5.9% |
| 3 | Palo Alto Investors | USD 39m | 5.4% |
| 4 | Deep Track Capital | USD 189m | 2.8% |
| 5 | Sphera Funds Management | USD 19m | 2.5% |
| 6 | Persistent Asset Partners | USD 4.6m | 1.4% |
| 7 | Viking Global Investors | USD 436m | 1.2% |
| 8 | Sofinnova Investments | USD 21m | 1.1% |
| 9 | Redmile Group | USD 15m | 1.0% |
| 10 | Eversept Partners | USD 14m | 0.7% |
Biomarin Pharmaceutical Inc trades under the symbol BMRN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 09061G101.
45 of the 720 hedge fund managers PPLI.com tracks reported Biomarin Pharmaceutical Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Viking Global Investors (USD 436m), Deep Track Capital (USD 189m), Millennium Management (USD 119m), Citadel Advisors (USD 64m) and Balyasny Asset Management (USD 60m).
45 managers in our coverage reported it, and between them they run 513 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Boone Capital Management, where the position was 7.8% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Biomarin Pharmaceutical Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.